本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688553 证券简称：汇宇制药 公告编号：2025-023 四川汇宇制药股份有限公司 首次公开发行限售股上市流通公告 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市 股数为 34,006,491 股。本公司确认，上市流通数量为该限售期的部分 首发限售股份数量。 本次股票上市流通总数为 34,006,491 股。 本次股票上市流通日期为 2025 年 4 月 28 日。因 2025 年 4 月 26 日为非交易日，故顺延至下一交易日。 一、本次上市流通的限售股类型 中国证券监督管理委员会于 2021 年 8 月 3 日出具《关于同意四川汇宇制药股 份有限公司首次公开发行股票注册的批复》（证监许可〔2021〕2596 号），同意四 川汇宇制药股份有限公司首次公开发行股票的注册申请。公司首次向社会公众公 开发行人民币普通股（A 股）股票 63,600,000 股，并于 2021 年 10 月 26 日在上海 证券交易所科创板上市，发行完成后总股 ...

中信建投证券股份有限公司 二、本次上市流通的限售股形成后至今公司股本数量变化情况 1 本次上市流通的限售股形成至今，公司未发生因利润分配、公积金转增导致 股本数量变化的情况。 三、首次公开发行出具的有关持股及减持意向的承诺 关于四川汇宇制药股份有限公司 首次公开发行限售股上市流通的核查意见 中信建投证券股份有限公司（以下简称"中信建投证券""保荐机构"）作 为四川汇宇制药股份有限公司(以下简称"汇宇制药"或"公司")首次公开发行 股票并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》等有关法律法规和规范性文件的要求，对汇 宇制药首次公开发行部分限售股上市流通的事项进行了核查，具体情况如下： 一、本次上市流通的限售股类型 中国证券监督管理委员会于2021年8月3日出具《关于同意四川汇宇制药股份 有限公司首次公开发行股票注册的批复》（证监许可〔2021〕2596号），同意四 川汇宇制药股份有限公司首次公开发行股票的注册申请。公司首次向社会公众公 开发行人民币普通股（A 股）股票63,600,000股，并于2021年10月26日在上海证 券交易所科创板上市，发行完成 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-024 四川汇宇制药股份有限公司 自愿披露注射用 HY05350 获得药物临床试验申请 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，四川汇宇制药股份有限公司（以下简称"公司"）全资子公司四川汇 宇海玥医药科技有限公司（以下简称"汇宇海玥"）收到国家药品监督管理局核 准签发的《受理通知书》，注射用 HY05350（项目研发代号为"HY-0005"）用 于治疗晚期实体瘤的临床试验申请获得受理。由于药品的研发周期长、审批环节 多，容易受到一些不确定性因素的影响，敬请广大投资者谨慎决策，注意防范投 资风险。现将相关情况公告如下： 一、药品基本情况 药品名称：注射用 HY05350 申请事项：境内生产药品注册临床试验 受理号：CXSL2500316 适应症：用于治疗晚期实体瘤。 申请人：四川汇宇海玥医药科技有限公司 审批结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 二、药品的其他相关情况 受理通知书的公告 四川汇宇制药股份有 ...

证券代码：688553 证券简称：汇宇制药 公告编号：2025-022 四川汇宇制药股份有限公司 自愿披露注射用 HY0001a 获得药物临床试验申请 申请事项：境内生产药品注册临床试验 受理号：CXSL2500294 适应症：用于治疗晚期实体瘤。 申请人：四川汇宇海玥医药科技有限公司 审批结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查， 决定予以受理。 二、药品的其他相关情况 受理通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，四川汇宇制药股份有限公司（以下简称"公司"）全资子公司四川汇 宇海玥医药科技有限公司（以下简称"汇宇海玥"）收到国家药品监督管理局核 准签发的《受理通知书》，注射用 HY0001a（项目研发代号为"HY-0001"）用 于治疗晚期实体瘤的临床试验申请获得受理。由于药品的研发周期长、审批环节 多，容易受到一些不确定性因素的影响，敬请广大投资者谨慎决策，注意防范投 资风险。现将相关情况公告如下： 一、药品基本情况 药品名称：注射用 HY0001a 注射用 HY000 ...

Core Viewpoint - The announcement indicates that Huiyu Pharmaceutical's wholly-owned subsidiary, Huiyu Haiyue, has received the acceptance notice from the National Medical Products Administration for the clinical trial application of injectable HY0001a for the treatment of advanced solid tumors, marking a significant milestone as it is the first drug targeting this specific site to enter clinical trials globally, with no similar products approved in the domestic or international markets [1] Group 1 - Huiyu Haiyue has received the acceptance notice for the clinical trial application of injectable HY0001a [1] - Injectable HY0001a is the first drug globally to disclose targeting this specific site for clinical trials [1] - There are currently no approved products targeting the same site in both domestic and international markets [1]

Group 1 - The major shareholder Huang Qianyi plans to reduce his stake in Huili Pharmaceutical by up to 12,708,000 shares, representing no more than 3% of the total shares, due to personal funding needs [1] - As of the announcement date, Huang Qianyi holds 27,219,439 shares, accounting for 6.426% of the company's total share capital [1] - Huili Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 26, 2021, with an initial public offering of 63.6 million shares at a price of 38.87 yuan per share [1] Group 2 - The total amount raised by Huili Pharmaceutical was 2.472 billion yuan, with a net amount of 2.361 billion yuan after deducting issuance costs, exceeding the original plan by 453 million yuan [2] - The funds raised are intended for the construction of the Huili EU standard injection industry base (Phase II), the Huili Innovative Drug Research Institute, and to supplement working capital [2] Group 3 - The total issuance costs amounted to 111 million yuan, with underwriting fees to CITIC Securities and Guodu Securities totaling 98.8748 million yuan [3]

Core Viewpoint - The major shareholder Huang Qianyi of Sichuan Huiyu Pharmaceutical Co., Ltd. plans to reduce his shareholding by up to 12,708,000 shares, representing no more than 3% of the company's total shares, due to personal funding needs [1][2]. Shareholder Reduction Plan - The reduction period is set from April 28, 2025, to July 26, 2025, starting 15 trading days after the announcement [1]. - The reduction will be executed through centralized bidding or block trading, with a maximum of 4,236,000 shares through centralized bidding and 8,472,000 shares through block trading [1][2]. - Huang Qianyi currently holds 27,219,439 shares, accounting for 6.426% of the total shares [1][2]. Compliance and Commitments - Huang Qianyi has committed to comply with relevant laws and regulations regarding the reduction, ensuring that the plan aligns with previous commitments made [3][4]. - The company will disclose any changes in the reduction plan based on market conditions and stock price fluctuations [3][4].

四川汇宇制药股份有限公司 证券代码：688553 证券简称：汇宇制药 公告编号：2025-021 持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 截至本公告披露之日，四川汇宇制药股份有限公司(以下简称"公司") 股东黄乾益持有公司股份数量为 27,219,439 股，占公司总股本的 6.426%；上述股份来源于公司首次公开发行前取得的股份，且已于 2022 年 10 月 26 日起解除限售并上市流通。 减持计划的主要内容 因自身资金需求，股东黄乾益拟通过集中竞价或大宗交易的方式减持 公司股份不超过 12,708,000 股，合计减持股份比例不超过公司股份总 数的 3%。 减持期间为自本公告披露之日起 15 个交易日后的 3 个月内。 若减持计划实施期间公司有派息、送股、资本公积金转增股本、配股 等除权除息事项，减持股份数将进行相应调整。 | 股东名称 | 黄乾益 | | | | --- | --- | --- | --- | | 股东身份 ...

Group 1 - China Aluminum reported a net profit of 12.4 billion yuan for 2024, an increase of 85.38% year-on-year, with a proposed cash dividend of 0.135 yuan per share [1] - Lihua Technology's net profit for 2024 decreased by 25.41% to 245 million yuan, with a proposed cash dividend of 0.7 yuan per 10 shares [1][2] - Zhongjing Food achieved a net profit of 175 million yuan in 2024, up 1.81% year-on-year, proposing a cash dividend of 8 yuan per 10 shares [3][4] - Sanwei Chemical's net profit fell by 6.92% to 263 million yuan, with a proposed cash dividend of 3 yuan per 10 shares [5] - Meino Biological's project for corn protein processing has received construction approval, with an investment of approximately 391 million yuan [6][7] Group 2 - Guangdian Electric's net profit surged by 411.28% to 74.73 million yuan, proposing a cash dividend of 0.7 yuan per 10 shares [13][14] - Xin'ao Co. reported a net profit of 4.493 billion yuan for 2024, down 36.64%, with a proposed cash dividend of 10.3 yuan per 10 shares [15] - Huaren Pharmaceutical's subsidiary received approval for a raw material drug, enhancing its product line [16] - Huanxin Technology received a project confirmation from BAIC Group for two display screen products, expected to enter mass supply [17] - Haitong Development plans to purchase four bulk carriers for a total of 59.25 million USD to expand its fleet [18] Group 3 - Guochuang High-tech won a bid for an asphalt procurement project worth 128 million yuan [22][23] - Huayi Pharmaceutical's subsidiary received overseas marketing approvals for several products [24] - Haisco's innovative drug HSK41959 has received clinical trial approval [25] - Hetai Machinery's subsidiary obtained a patent for a dust-proof chain technology [28] - Le Xin Medical's fetal heart rate monitor registration renewal application has been accepted [29] Group 4 - Feilong Co. became a designated supplier for an international client's electronic oil pump project, with expected sales of approximately 160 million yuan [29] - Yunnan Copper reported a net profit of 1.265 billion yuan for 2024, down 19.9%, with a proposed cash dividend of 2.4 yuan per 10 shares [42] - China Merchants Bank's net profit increased by 1.22% to 148.39 billion yuan, proposing a cash dividend of 20 yuan per 10 shares [43] - Shuanghui Development's net profit decreased by 1.26% to 4.989 billion yuan, with a proposed cash dividend of 7.5 yuan per 10 shares [44]